Craig-Hallum Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $24
Craig-Hallum analyst Adam Vogel initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Buy rating and announces Price Target of $24.
Stocks · News reference
FDA Clears Satellos Bioscience’s IND Application For Forazapadin For Treatment Of Facioscapulohumeral Muscular Dystrophy
FDA clearance expands development of forazapadin into a second degenerative muscle disease with significant unmet medical needFSHD Canada Foundation to provide up to US$5 million in non-dilutive financing toward the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform
Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that the United States
Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
Satellos Bioscience received FDA clearance for its IND application to test forazapadin in facioscapulohumeral muscular dystrophy (FSHD), expanding the drug candidate into a second degenerative muscle disease. The FSHD Canada Foundation will provide up to US$5 million in non-dilutive financing to support clinical development, with a Phase 2 study expected to begin in Q4 2026. Forazapadin is an AAK1 inhibitor designed to restore muscle repair and regeneration.